End stage renal disease (ESRD) is simultaneously associated with immune activation, marked by systemic inflammation, and immune deficiency. Systemic inflammation contributes to atherosclerosis, cardiovascular disease, cachexia and anemia, while immune deficiency leads to impaired response to vaccination, and increased incidence and severity of microbial infections. ESRD-associated inflammation and immune deficiency are associated with: a) General expansion of monocytes and elevations of their basal integrin, Toll-like receptor (TLR)-2, and TLR-4 expression, cytokine production, and reactive oxygen species (ROS) generation and reduced phagocytic capacity, b) Depletion and impaired inhibitory activity of regulatory T cells (Treg), c) Spontaneous activation, degranulation, increased basal ROS production, decreased phagocytic capacity and increased apoptosis of the circulating polymorphonuclear leukocytes (PMNs), d) Upregulation of ROS production machinery and chemokine expression in the cellular constituents of various tissues, highlighting participation of non-immune cells in the prevailing inflammatory state. e) Depletion of the antigen-presenting dendritic cells (DC), f) Reduced CD4/CD8 T cell ratio and depletion of naïve and central memory T cells, g) Diffuse B cell lymphopenia leading to impaired humoral immunity, and h) Increased pro-inflammatory activity of LDL and reduced anti-inflammatory capacity of HDL. Thus, ESRD-associated inflammation is due to activation of innate immune system, orchestrated by monocytes, macrophages, granulocytes and cellular constituents of other organs/tissues. This is coupled with immune deficiency which is caused by depletion of dendritic cell, naïve and central memory T cells and B cells and impaired phagocytic function of PMNs and monocytes.